^
Association details:
| Biomarker: | PD-L1 overexpression + RET-KIF5B fusion + TP53 mutation + AR mutation + RET rearrangement |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Frontline pembrolizumab for the treatment of RET-rearranged non-small cell lung cancer: A case report
Published date:
06/16/2021
Excerpt:
A 71-year-old never-smoker Caucasian man...A biopsy from the lung mass revealed poorly differentiated adenocarcinoma of lung primary...Immunohistochemistry (IHC) for PD-L1...demonstrated tumor proportion score of 100%... Next generation sequencing...revealed KIF5B-RET fusion (4.9% of DNA)...In addition, concurrent TP53 (13.4%) and AR (0.2%) mutations were reported. FISH confirmed RET rearrangement...pembrolizumab...was initiated....Follow-up MRI and CT scan at 6 months after treatment showed a complete response...
DOI:
10.1016/j.ctarc.2021.100423
